Mnemo Therapeutics, a biotechnology company developing transformational immunotherapies, announced a publication in Cell Reports that demonstrates peptides derived from transposable elements (TEs) – mobile...
Amytrx and Amarex Clinical Research, LLC, an NSF company, announced they are initiating the Phase II clinical trial on atopic dermatitis (AD) using Amytrx's...
REGENXBIO Inc. is celebrating the opening of its new Manufacturing Innovation Center gene therapy manufacturing facility.
Also Read: Updated Data for Janssen’s Bispecific Teclistamab Suggest...
CyanVac LLC, a clinical-stage biopharmaceutical company developing intranasal vaccines using a proprietary transformational parainfluenza virus 5 (PIV5)-based vector, announced preclinical data in a hamster...
The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab Phase 1/2 MajesTEC-1 study.1 Teclistamab is an...
